Table 3.
Characteristics of cancers detected
| Continuous variables | Number of biopsy sessions | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 (n=60) | 2 (n=81) | 3 (n=35) | ⩾4 (n=22) | P | Total (n=198) | ||||||
| Mean | Median | Mean | Median | Mean | Median | Mean | Median | Mean | Median | ||
| Number mapping cores | 54.2 | 54.0 | 55.8 | 57.0 | 53.9 | 58.0 | 54.5 | 58.5 | 0.603 | 54.8 | 56.0 |
| Mean % positive biopsies | 22.4 | 13.4 | 15.9 | 10.9 | 15.5 | 12.5 | 17.7 | 6.4 | 0.256 | 18.0 | 12.1 |
| Categorical variables | Number of patients with prostate cancer | |||||
|---|---|---|---|---|---|---|
| Count (%) | Count (%) | Count (%) | Count (%) | P | Count (%) | |
| Gleason score | ||||||
| 6 | 24 (40.0) | 38 (46.9) | 17 (48.6) | 9 (40.9) | 0.183 | 88 (44.4) |
| 7 | 26 (43.3) | 37 (45.7) | 10 (28.6) | 8 (36.4) | 81 (40.9) | |
| 8–10 | 10 (16.7) | 6 (7.4) | 8 (22.9) | 5 (22.7) | 29 (14.6) | |
| No. positive cores | ||||||
| 1–4 | 22 (36.7) | 28 (34.6) | 14 (40) | 13 (59.1) | 0.643 | 77 (38.9) |
| 5–12 | 21 (35.0) | 34 (42) | 13 (37.1) | 3 (13.6) | 71 (35.8) | |
| >12 | 17 (28.3) | 19 (23.5) | 8 (22.9) | 6 (27.3) | 50 (25.3) | |
| Prebiopsy diagnosis | ||||||
| PIN | 0 (0) | 3 (3.7) | 1 (2.9) | 0 (0) | 0.002 | 4 (2.0) |
| Elevated PSA | 60 (100) | 65 (80.2) | 28 (80.0) | 19 (86.4) | 172 (86.9) | |
| ASAP | 0 (0) | 13 (16.0) | 6 (17.1) | 3 (13.6) | 22 (11.1) | |
Abbreviations: ASAP, atypical small acinar proliferation; PIN, prostatic intraepithelial neoplasia; PSA, prostate specific antigen.
Italic indicates significance test.